Vaccine (mRNA vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Arcturus Therapeutics
ARCT-154 is a self-amplifying RNA vaccine against SARS-CoV-2, the virus that causes COVID-19. It is studied for prevention of COVID-19 and SARS-CoV-2 infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05012943 | Phase 2/3 | COVID-19 Vaccines | Completed | ARCT |
| NCT05037097 | Phase 1/2 | COVID-19 | Completed | ARCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Corona Virus InfectionCOVID-19COVID-19 VaccinesSARS-CoV-2 Infection
Updated Oct 11, 2026. Something wrong or missing? Report it on the ARCT page.
See ARCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARCT catalysts and pipeline →